Drugs / E7 T-Cell Receptor (TCR)
E7 T-Cell Receptor (TCR)
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04476251 | Jan → Sep 2021 | cervical cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04015336 | Jul 2020 | human papilloma virus infection, oropharynx cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT03937791 | Oct 2019 → Jun 2020 | vulvar intraepithelial neoplasia | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E7 T-Cell Receptor (TCR) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04015336 ↗ |
| Known as | E7 TCR T cells | “In this clinical trial the HPV-16 infection is targeted with a single infusion of autologous T cells that have been genetically engineered to express a HPV-16 E7-specific T...” NCT03937791 ↗ |
| Known as | TCR+ cells | “Patients will receive up to 3x10\^10 E7 T-Cell Receptor (TCR) T cells (i.e. TCR+ cells).” NCT04476251 ↗ |
| Modality | Cell therapy | “single infusion of autologous T cells that have been genetically engineered” NCT03937791 ↗ |
| Route | Intravenous | “will be administered intravenously” NCT03937791 ↗ |